Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
By Andrew Powaleny | April 6, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for...
Read More
The biopharmaceutical industry’s unique role in responding to COVID-19
By Richard Moscicki, M.D. | April 2, 2020
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock...
Read More
COVID-19 Response: Supporting the frontline
By Stephen J. Ubl | March 30, 2020
Updated 4/8/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...
Read More
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
By Guest Contributor | March 26, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
America’s biopharmaceutical companies are working around the clock to beat coronavirus
By Holly Campbell | March 20, 2020
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment to finding solutions to prevent,...
Read More
Guest post: Takeda’s efforts to address COVID-19
By Guest Contributor | March 19, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest ...
Read More
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
By Andrew Powaleny | March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...
Read More
ICYMI: Continued biopharmaceutical action on COVID-19
By Andrew Powaleny | March 6, 2020
Updated 3/11/2020 This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry’s response to COVID-19, a...
Read More
Helping those affected by the coronavirus
By Stephen J. Ubl | February 20, 2020
Updated as of 4/8/2020 America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus...
Read More
Why vaccines work in the fight against measles and other infectious diseases
By Richard Moscicki, M.D. | February 13, 2019
It is often said that vaccines are only second to clean drinking water in terms of public health impact. In recent years, misinformation about vaccines, especially childhood vaccinations, has...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
